SBI-101

Sentien Biotechnologies, Inc. · Phase 1 active Biologic

At a glance

Generic name	SBI-101
Sponsor	Sentien Biotechnologies, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy (PHASE1, PHASE2)
A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SBI-101 CI brief — competitive landscape report
SBI-101 updates RSS · CI watch RSS
Sentien Biotechnologies, Inc. portfolio CI